Cargando…

KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery

We report on a woman with aggressive estrogen receptor‐positive, KRAS‐mutated ovarian cancer who achieved a remarkable response to combination therapy with the MEK inhibitor (trametinib) and the aromatase inhibitor (letrozole), even though the disease had failed to respond to a combination of a PI3K...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Shumei, McFall, Thomas, Takahashi, Kenta, Bamel, Kasey, Ikeda, Sadakatsu, Eskander, Ramez N., Plaxe, Steven, Parker, Barbara, Stites, Edward, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018312/ https://www.ncbi.nlm.nih.gov/pubmed/33528846 http://dx.doi.org/10.1002/onco.13702

Ejemplares similares

Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
por: Kollipara, Revathi, et al.
Publicado: (2017)

Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center
por: Sharabi, Andrew, et al.
Publicado: (2017)

A mechanism for the response of KRAS(G13D) expressing colorectal cancers to EGFR inhibitors
por: McFall, Thomas, et al.
Publicado: (2020)

Biomarkers for Programmed Death‐1 Inhibition in Prostate Cancer
por: Manogue, Charlotte, et al.
Publicado: (2018)

Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification
por: Hempel, Dirk, et al.
Publicado: (2020)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy‐Refractory Testicular Tumors
por: Lian, Bijun, et al.
Publicado: (2019)

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2‐Year Durable Response
por: Valiakhmetova, Andge, et al.
Publicado: (2019)

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD‐1/PDL‐1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer
por: Winer, Arthur, et al.
Publicado: (2019)

Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein‐Drug Docking
por: Yu, Nian, et al.
Publicado: (2021)

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion
por: Morabito, Alessandro, et al.
Publicado: (2022)

Complete Pathological Response After Neoadjuvant Short‐Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI‐H/dMMR Rectal Cancer
por: Trojan, Jörg, et al.
Publicado: (2021)

BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1‐Rearranged Non‐Small Cell Lung Cancer: A Case Report
por: Li, Juan, et al.
Publicado: (2021)

Novel SLC12A2‐ROS1 Fusion in Non‐Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next‐Generation Sequencing Assay
por: Rodríguez‐Antolín, Carlos, et al.
Publicado: (2021)

Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy
por: Nardi, Valentina, et al.
Publicado: (2022)

Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit
por: Dong, Sharlene, et al.
Publicado: (2022)

Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review
por: Gim, Gahyun, et al.
Publicado: (2022)

KIT-Associated Familial GIST Syndrome: Response to Tyrosine Kinase Inhibitors and Implications for Risk Management
por: Brodey, Alexandra, et al.
Publicado: (2022)

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma
por: Turpin, Anthony, et al.
Publicado: (2023)

Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series
por: Brett, Jamie O, et al.
Publicado: (2022)

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53
por: Scarpetti, Lauren, et al.
Publicado: (2023)

Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board
por: Xavier, Camila B, et al.
Publicado: (2023)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Prolonged Survival of NUT Midline Carcinoma and Current Approaches to Treatment
por: Kaplan, Henry G, et al.
Publicado: (2023)

Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer
por: Hunt, Allison L, et al.
Publicado: (2023)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation
por: Zhao, Jing, et al.
Publicado: (2023)

Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome
por: File, Danielle M., et al.
Publicado: (2020)

Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary
por: Martinez, Francisco, et al.
Publicado: (2021)

Infantile ZFTA Fusion–Positive Tumor of the Posterior Fossa: Molecular Tumor Board
por: Paulson, Vera A., et al.
Publicado: (2023)

Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
por: Hamdan, Diaddin, et al.
Publicado: (2023)

Longitudinal Molecular Analysis of Tumor Exome and Transcriptome to Evaluate Clonal Evolution and Identify Novel Therapeutic Targets in Thymoma
por: Nabel, Christopher S., et al.
Publicado: (2023)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors
por: McFall, Thomas, et al.
Publicado: (2020)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
por: Cohen, Philip R., et al.
Publicado: (2017)

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
por: Kato, Shumei, et al.
Publicado: (2020)

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
por: Khemlina, Galina, et al.
Publicado: (2017)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
por: Ikeda, Sadakatsu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3ufra8jpj49dop52bbju23pngt